Patents by Inventor Ofer WISER

Ofer WISER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING HEARING LOSS
    Publication number: 20250057886
    Abstract: Provided herein are methods for inducing cellular differentiation of undifferentiated stem cells into cells capable of functioning as sensory cells of the ear, and to pharmaceutical compositions for treating auditory conditions in a subject.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 20, 2025
    Inventors: Olga MIZRAHI, Rami SKALITER, Francois BINETTE, Dana HAYOUN NEEMAN, Ofer WISER, Lilach ALON
  • Preparation of retinal pigment epithelium cells
    Patent number: 12203097
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: January 21, 2025
    Assignee: CELL CURE NEUROSCIENCES LTD.
    Inventors: Osnat Bohana-Kashtan, Ofer Wiser
  • Preparation of retinal pigment epithelium cells
    Patent number: 12188047
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: January 7, 2025
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., CELL CURE NEUROSCIENCES LTD.
    Inventors: Benjamin Eithan Reubinoff, Orna Singer, Osnat Bohana-Kashtan, Ofer Wiser
  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20240301351
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS
    Publication number: 20240299625
    Abstract: Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.
    Type: Application
    Filed: December 5, 2023
    Publication date: September 12, 2024
    Inventors: Rami Skaliter, Gary Hogge, Jordi Mones, Avi Ben Shabat, Lilach Alon, Ravid Tikotzki, Dana Hayoun Neeman, Ofer Wiser
  • EXPANSION OF RETINAL PIGMENT EPITHELIUM CELLS
    Publication number: 20240285693
    Abstract: Presented herein are methods and compositions for expanding RPE cells with the use of a suspendable cell support matrix. Also provided are pharmaceutical compositions containing RPE cells, and methods of treating an eye disorder or disease using RPE cells.
    Type: Application
    Filed: January 26, 2024
    Publication date: August 29, 2024
    Inventors: Dana Hayoun Neeman, Ofer Wiser, Ravid Tikotzki, Lilach Alon
  • RPE cell populations and methods of generating same
    Patent number: 11987810
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: May 21, 2024
    Assignee: CELL CURE NEUROSCIENCES LTD.
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • METHODS OF GENERATING OLIGODENDROCYTE PROGENITOR CELLS AND USE THEREOF
    Publication number: 20240158745
    Abstract: Methods for differentiating human pluripotent stem cells to oligodendrocyte progenitor cells (OPCs) are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs.
    Type: Application
    Filed: March 10, 2022
    Publication date: May 16, 2024
    Inventors: Rami SKALITER, Francois BINETTE, Dana HAYOUN NEEMAN, Assaf BAHAT, Ofer WISER
  • RPE cell populations and methods of generating same
    Patent number: 11891622
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 6, 2024
    Assignee: CELL CURE NEUROSCIENCES LTD.
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • COMPOSITIONS AND METHODS FOR EMBRYONIC STEM CELL EXPANSION
    Publication number: 20230313127
    Abstract: Provided herein are methods and compositions for expansion of human embryonic stem with suspendable expansion complexes including microcarriers.
    Type: Application
    Filed: August 10, 2021
    Publication date: October 5, 2023
    Inventors: Lilach ALON, Rami SKALITER, Ravid TIKOTZKI, Dana HAYOUN NEEMAN, Ofer WISER
  • RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONS
    Publication number: 20230119816
    Abstract: Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 20, 2023
    Inventors: Nir Netzer, Ofer Wiser, Bat Shahaf, Orit Gamburg, Lior Rosenberg Belmaker, Dana Hayoun Neeman, Osnat Bohana Kashtan
  • ASSESSING RETINAL PIGMENT EPITHELIAL CELL POPULATIONS
    Publication number: 20230051803
    Abstract: A method of qualifying whether a cell population is a suitable therapeutic for treating an eye condition is disclosed. The method comprises analyzing co-expression of premelanosome protein (PMEL17) and at least one polypeptide selected from the group consisting of cellular retinaldehyde binding protein (CRALBP), lecithin retinol acyltransferase (LRAT) and sex determining region Y-box 9 (SOX 9) in the population of cells.
    Type: Application
    Filed: August 8, 2022
    Publication date: February 16, 2023
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONS
    Publication number: 20220408719
    Abstract: Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.
    Type: Application
    Filed: August 23, 2022
    Publication date: December 29, 2022
    Inventors: Nir Netzer, Ofer Wiser, Bat Shahaf, Orit Gamburg, Lior Rosenberg Belmaker, Dana Hayoun Neeman, Osnat Bohana Kashtan
  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20220169982
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 2, 2022
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20220169981
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 2, 2022
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20220154141
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: December 8, 2021
    Publication date: May 19, 2022
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONS
    Publication number: 20220095608
    Abstract: Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Nir NETZER, Ofer WISER, Bat SHAHAF, Orit GAMBURG, Lior ROSENBERG BELMAKER, Dana HAYOUN NEEMAN, Osnat BOHANA KASHTAN
  • PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLS
    Publication number: 20210388316
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 16, 2021
    Inventors: Osnat Bohana-Kashtan, Ofer Wiser
  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20210332325
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: May 18, 2021
    Publication date: October 28, 2021
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • Preparation of retinal pigment epithelium cells
    Patent number: 11066642
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: July 20, 2021
    Assignee: Cell Cure Neurosciences LTD
    Inventors: Osnat Bohana-Kashtan, Ofer Wiser